Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 7.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,078,453 shares of the biopharmaceutical company’s stock after acquiring an additional 78,143 shares during the period. Geode Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $402,138,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. Whittier Trust Co. increased its holdings in shares of Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 45 shares during the last quarter. AdvisorNet Financial Inc increased its holdings in shares of Regeneron Pharmaceuticals by 208.0% in the 4th quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 52 shares during the last quarter. Captrust Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $30,000. Intercontinental Wealth Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $33,000. Finally, Blume Capital Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $36,000. Institutional investors own 67.63% of the company’s stock.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Neil Stahl sold 9,853 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the sale, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The disclosure for this sale can be found here. Over the last three months, insiders sold 141,968 shares of company stock valued at $57,360,056. Insiders own 11.84% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). The firm had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the company earned $4.67 earnings per share. As a group, research analysts forecast that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current fiscal year.
A number of research firms have recently commented on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reiterated a “hold” rating and issued a $441.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. Piper Jaffray Companies increased their price objective on Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Guggenheim downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $466.00 to $425.00 in a report on Friday, February 22nd. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price objective on the stock in a report on Thursday, February 7th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $404.88.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: Conference Calls
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.